Alpha1-antitrypsin deficiency: forgotten etiology.

OBJECTIVE

To provide a review of alpha1-antitrypsin deficiency (AATD), alpha1-antitrypsin (AAT) augmentation, and the recommendations for timely recognition and treatment.

SOURCES OF INFORMATION

Published guidelines and the medical literature about AATD and AAT augmentation were reviewed. The information presented is based on available published literature obtained by searching PubMed, the Cochrane Library databases, and the reference lists of relevant articles. Searches were limited to English-language articles published between 1990 and 2009.

MAIN MESSAGE

Alpha1-antitrypsin deficiency, a genetic disorder characterized by low serum levels of AAT, predisposes affected patients to development of early-onset pulmonary disease (most commonly emphysema and chronic obstructive pulmonary disease) and occasionally even life-threatening liver disease. Despite being one of the most common inherited conditions (affecting about 1 in 2000 to 5000 people), AATD is underrecognized. This is unfortunate; although there is no cure for AATD, prompt diagnosis can help impede loss of lung function. Specific treatment of this deficiency with augmentation therapy is effective.

CONCLUSION

Alpha1-antitrypsin deficiency is a common genetic condition that can be involved in premature lung and liver disease. Consider the diagnosis to allow earlier institution of AAT augmentation therapy to slow the progression of premature lung disease in affected patients.